Leukocyte chemotactic factor 2-related amyloidosis presenting with severe jaundice and hepatic encephalopathy

Hussam Almasri; Almurtada Razok; Ahmed Badi; Muneera Almohannadi; Abdo Lutf; Mahir Petkar; Abdelnaser Elzouki

doi:10.1002/ccr3.5185

Leukocyte chemotactic factor 2-related amyloidosis presenting with severe jaundice and hepatic encephalopathy

Clin Case Rep. 2021 Dec 5;9(12):e05185. doi: 10.1002/ccr3.5185. eCollection 2021 Dec.

Authors

Hussam Almasri¹, Almurtada Razok¹, Ahmed Badi², Muneera Almohannadi², Abdo Lutf¹, Mahir Petkar³, Abdelnaser Elzouki¹

Affiliations

¹ Department of Medicine Hamad Medical Corporation Doha Qatar.
² Department of gastroenterology and hepatology Hamad Medical Corporation Doha Qatar.
³ Department of Pathology Hamad Medical Corporation Doha Qatar.

Abstract

Amyloidosis is a well-known disease with various types and subtypes. One of the most recently identified types is leukocyte chemotactic factor 2 amyloidosis (LECT 2), which was found to be common in certain ethnic backgrounds. It is suggested that the diagnosis of this type is vital to prevent any therapy-related complications when it is erroneously diagnosed as AL amyloidosis. The clinical presentation is usually slowly progressive kidney disease and mild hepatic impairment. We report a case of LECT2 amyloidosis, which presented with severe painless cholestasis and hepatic encephalopathy alongside progressive kidney disease.

Keywords: Leukocyte chemotactic factor 2 amyloidosis; cholestasis; end‐stage renal disease.

Publication types

Case Reports